Journal of Diagnostics Concepts & Practice ›› 2018, Vol. 17 ›› Issue (01): 11-18.doi: 10.16150/j.1671-2870.a2767
• Experts forum • Previous Articles Next Articles
Received:2017-01-20
Published:2018-02-25
CLC Number:
Add to citation manager EndNote|Ris|BibTeX
URL: https://www.qk.sjtu.edu.cn/jdcp/EN/10.16150/j.1671-2870.a2767
| [1] Zhang L, Long J, Jiang W, et al.Trends in Chronic Kidney Disease in China[J]. N Engl J Med,2016,375(9):905-906. [2] Han Q, Zhu H, Chen X, et al.Non-genetic mechanisms of diabetic nephropathy[J]. Front Med,2017,11(3):319-332. [3] Collins AJ, Foley RN, Chavers B, et al. 'United States Renal Data System2011 Annual Data Report: Atlas of chronic kidney disease & end-stage renal disease in the United States[J]. Am J Kidney Dis,2012,59(1 Suppl 1):A7,e1-e420. [4] van Dijk PR, Kramer A, Logtenberg SJ, et al. Incidence of renal replacement therapy for diabetic nephropathy in the Netherlands: Dutch diabetes estimates(DUDE)-3)[J]. BMJ Open,2015,5(1):e005624. [5] Toppe C, Möllsten A, Schön S, et al.Renal replacement therapy due to type 1 diabetes; time trends during 1995-2010--a Swedish population based register study[J]. J Dia-betes Complications,2014,28(2):152-155. [6] Assogba FG, Couchoud C, Hannedouche T, et al.Trends in the epidemiology and care of diabetes mellitus-related end-stage renal disease in France, 2007-2011[J]. Diabetologia,2014,57(4):718-728. [7] Yang SH, Dou KF, Song WJ.Prevalence of diabetes among men and women in China[J]. N Engl J Med,2010, 362(25):2425-2426. [8] Xu Y, Wang L, He J, et al.Prevalence and control of dia-betes in Chinese adults[J]. JAMA,2013,310(9):948-959. [9] Maki T, Maeda Y, Sonoda N, et al.Renoprotective effect of a novel selective PPARα modulator K-877 in db/db mice: A role of diacylglycerol-protein kinase C-NAD(P)H oxidase pathway[J]. Metabolism,2017,71:33-45. [10] Quadri SS, Culver SA, Li C, et al.Interaction of the renin angiotensin and cox systems in the kidney[J]. Front Biosci (Schol Ed),2016,8:215-826. [11] Kawanami D, Matoba K, Utsunomiya K.Signaling pathways in diabetic nephropathy[J]. Histol Histopathol,31(10):1059-1067. [12] Lu Z, Liu N, Wang F.Epigenetic Regulations in Diabetic Nephropathy[J]. J Diabetes Res,2017,2017:7805058. [13] Tziastoudi M, Stefanidis I, Hadjigeorgiou GM, et al.A systematic review and meta-analysis of genetic association studies for the role of inflammation and the immune system in diabetic nephropathy[J]. Clin Kidney J,2017, 10(3):293-300. [14] Gnudi L, Coward RJM, Long DA.Diabetic Nephropathy: Perspective on Novel Molecular Mechanisms[J]. Trends Endocrinol Metab,2016,27(11):820-830. [15] Yang M, Xu J, Yu J, et al.Anti-inflammatory effects of 1,25-dihydroxyvitamin D3 in monocytes cultured in serum from patients with type 2 diabetes mellitus and diabetic nephropathy with uremia via Toll-like receptor 4 and nuclear factor-κB p65[J]. Mol Med Rep,2015,12(6):8215-8222. [16] Zhang X, Zhou M, Guo Y, et al.1,25-Dihydroxyvitamin D3 Promotes High Glucose-Induced M1 Macrophage Switching to M2 [17] von Scholten BJ, Reinhard H, Hansen TW, et al. Markers of inflammation and endothelial dysfunction are associa-ted with incident cardiovascular disease, all-cause morta-lity, and progression of coronary calcification in type 2 diabetic patients with microalbuminuria[J]. J Diabetes Complications,2016,30(2):248-255. [18] Aghadavod E, Khodadadi S, Baradaran A, et al.Role of Oxidative Stress and Inflammatory Factors in Diabetic Kidney Disease[J]. Iran J Kidney Dis,2016,10(6):337-343. [19] Fortpied J, Vertommen D, van Schaftingen E. Binding of mannose-binding lectin to fructosamines: a potential link between hyperglycaemia and complement activation in diabetes[J]. Diabetes Metab Res Rev,2010,26(4):254-260. [20] Wu XH, Huang SM, Fan WX, et al.Influence of high glucose and mannose binding lectin complement pathway activation to IL-6 and TNF-alpha's expression by human renal glomerular endothelial cells[J]. Sichuan Da Xue Xue Bao Yi Xue Ban,2011,42(1):90-94. [21] Flyvbjerg A.The role of the complement system in diabetic nephropathy[J]. Nat Rev Nephrol,2017,13(5):311-318. [22] Nangaku M, Pippin J, Couser WG.C6 mediates chronic progression of tubulointerstitial damage in rats with remnant kidneys[J]. J Am Soc Nephrol,2002,13(4):928-936. [23] Morita Y, Ikeguchi H, Nakamura J, et al.Complement activation products in the urine from proteinuric patients[J]. J Am Soc Nephrol,2000,11(4):700-707. [24] Acosta J, Hettinga J, Flückiger R, et al.Molecular basis for a link between complement and the vascular complications of diabetes[J]. Proc Natl Acad Sci U S A,2000, 97(10):5450-5455. [25] Qin X, Goldfine A, Krumrei N, et al.Glycation inactivation of the complement regulatory protein CD59: a possible role in the pathogenesis of the vascular complications of human diabetes[J]. Diabetes,2004,53(10):2653-2661. [26] Wang H, Vinnikov I, Shahzad K, et al.The lectin-like domain of thrombomodulin ameliorates diabetic glomerulopathy [27] Li L, Chen L, Zang J, et al.C3a and C5a receptor anta-gonists ameliorate endothelial-myofibroblast transition [28] Li L, Yin Q, Tang X, et al.C3a receptor antagonist ameliorates inflammatory and fibrotic signals in type 2 diabetic nephropathy by suppressing the activation of TGF-β/smad3 and IKBα pathway[J]. PLoS One,2014,9(11):e113639. [29] Fujita T, Ohi H, Komatsu K, et al.Complement activation accelerates glomerular injury in diabetic rats[J]. Nephron,1999,81(2):208-214. [30] Ghosh P, Sahoo R, Vaidya A, et al.Role of complement and complement regulatory proteins in the complications of diabetes[J]. Endocr Rev,2015,36(3):272-288. [31] Morgan BP, Harris CL.Complement, a target for therapy in inflammatory and degenerative diseases[J]. Nat Rev Drug Discov,2015,14(12):857-877. [32] Loeffler I, Wolf G.Epithelial-to-Mesenchymal Transition in Diabetic Nephropathy: Fact or Fiction?[J]. Cells,2015, 4(4):631-652. [33] Mason RM, Wahab NA.Extracellular matrix metabolism in diabetic nephropathy[J]. J Am Soc Nephrol,2003,14(5):1358-1373. [34] Yamaguchi Y, Iwano M, Suzuki D, et al.Epithelial-mesenchymal transition as a potential explanation for podocyte depletion in diabetic nephropathy[J]. Am J Kidney Dis,2009,54(4):653-664. [35] Duan SB, Liu GL, Wang YH, et al.Epithelial-to-mese-nchymal transdifferentiation of renal tubular epithelial cell mediated by oxidative stress and intervention effect of probucol in diabetic nephropathy rats[J]. Ren Fail,2012,34(10):1244-1251. [36] Nasri H.On the occasion of the world diabetes day 2013; diabetes education and prevention; a nephrology point of view[J]. J Renal Inj Prev,2013,2(2):31-32. [37] Inagi R, Ishimoto Y, Nangaku M.Proteostasis in endoplasmic reticulum--new mechanisms in kidney disease[J]. Nat Rev Nephrol,2014,10(7):369-378. [38] He F, Chen S, Wang H, et al.Regulation of CD2-asso-ciated protein influences podocyte endoplasmic reticulum stress-mediated apoptosis induced by albumin overload[J]. Gene,2011,484(1-2):18-25. [39] Chen S, He FF, Wang H, et al.Calcium entry [40] Ito N, Nishibori Y, Ito Y, et al.mTORC1 activation triggers the unfolded protein response in podocytes and leads to nephrotic syndrome[J]. Lab Invest,2011,91(11):1584-1595. [41] Shimizu M, Furuichi K, Toyama T, et al.Long-term outcomes of Japanese type 2 diabetic patients with biopsy-proven diabetic nephropathy[J]. Diabetes Care,2013,36(11):3655-3662. [42] Zhu X, Xiong X, Yuan S, et al.Validation of the interstitial fibrosis and tubular atrophy on the new pathological classification in patients with diabetic nephropathy: A single-center study in China[J]. J Diabetes Complications,2016,30(3):537-541. [43] Mise K, Hoshino J, Ubara Y, et al.Renal prognosis a long time after renal biopsy on patients with diabetic nephropathy[J]. Nephrol Dial Transplant,2014,29(1):109-118. [44] Tunçdemir M, Öztürk M.Regulation of the Ku70 and apoptosis-related proteins in experimental diabetic nephropathy[J]. Metabolism,2016,65(10):1466-1477. [45] Westermann B.Mitochondrial fusion and fission in cell life and death[J]. Nat Rev Mol Cell Biol,2010,11(12):872-884. [46] Wang W, Wang Y, Long J, et al.Mitochondrial fission triggered by hyperglycemia is mediated by ROCK1 activation in podocytes and endothelial cells[J]. Cell Metab,2012,15(2):186-200. [47] Cowie CC, Port FK, Wolfe RA, et al.Disparities in incidence of diabetic end-stage renal disease according to race and type of diabetes[J]. N Engl J Med,1989,321(16):1074-1079. [48] Regele F, Jelencsics K, Shiffman D, et al. Genome-wide studies to identify risk factors for kidney disease with a focus on patients with diabetes[J]. Nephrol Dial Transplant,2015,30(Suppl 4):iv26-iv34. [49] Pirola L, Balcerczyk A, Okabe J, et al.Epigenetic phenomena linked to diabetic complications[J]. Nat Rev Endocrinol,2010,6(12):665-675. [50] 王惠珍, 文枫, 王文健, 非编码RNA参与糖尿病肾病发病的机制及其诊疗价值[J]. 中华肾脏病杂志,2016(9):708-712. [51] Mohan A, Singh RS, Kumari M, et al.Urinary Exosomal microRNA-451-5p Is a Potential Early Biomarker of Dia-betic Nephropathy in Rats[J]. PLoS One,2016,11(4):e0154055. [52] Tonna S, El-Osta A, Cooper ME, et al.Metabolic memory and diabetic nephropathy: potential role for epigenetic mechanisms[J]. Nat Rev Nephrol,2010,6(6):332-341. [53] Gnudi L, Benedetti S, Woolf AS, et al.Vascular growth factors play critical roles in kidney glomeruli[J]. Clin Sci (Lond),2015,129(12):1225-1236. [54] Sivaskandarajah GA, Jeansson M, Maezawa Y, et al.Vegfa protects the glomerular microvasculature in diabetes[J]. Diabetes,2012,61(11):2958-2966. [55] Sharma D, Bhattacharya P, Kalia K, et al.Diabetic nephropathy: New insights into established therapeutic paradigms and novel molecular targets[J]. Diabetes Res Clin Pract,2017,128:91-108. [56] de Zeeuw D, Coll B, Andress D, et al. The endothelin antagonist atrasentan lowers residual albuminuria in patients with type 2 diabetic nephropathy[J]. J Am Soc Nephrol,2014,25(5):1083-1093. [57] Keen H, Chlouverakis C.An immunoassay method for urinary albumin at low concentrations[J]. Lancet,1963, 2(7314):913-914. [58] Viberti GC, Jarrett RJ, Keen H.Microalbuminuria as prediction of nephropathy in diabetics[J]. Lancet,1982, 2(8298):611. [59] Mauer M, Zinman B, Gardiner R, et al.Renal and retinal effects of enalapril and losartan in type 1 diabetes[J]. N Engl J Med,2009,361(1):40-51. [60] Perkins BA, Ficociello LH, Roshan B, et al.In patients with type 1 diabetes and new-onset microalbuminuria the development of advanced chronic kidney disease may not require progression to proteinuria[J]. Kidney Int,2010, 77(1):57-64. [61] MacIsaac RJ, Panagiotopoulos S, McNeil KJ, et al. Is nonalbuminuric renal insufficiency in type 2 diabetes related to an increase in intrarenal vascular disease?[J]. Diabetes Care,2006,29(7):1560-1566. [62] Caramori ML, Fioretto P, Mauer M.Low glomerular filtration rate in normoalbuminuric type 1 diabetic patients: an indicator of more advanced glomerular lesions[J]. Diabetes,2003,52(4):1036-1040. [63] Tuttle KR, Bakris GL, Bilous RW, et al.Diabetic kidney disease: a report from an ADA Consensus Conference[J]. Diabetes Care,2014,37(10):2864-2883. [64] Kramer HJ, Nguyen QD, Curhan G, et al.RRenal insufficiency in the absence of albuminuria and retinopathy among adults with type 2 diabetes mellitus[J]. JAMA,2003,289(24):3273-3277. [65] Molitch ME, Steffes M, Sun W, et al.Development and progression of renal insufficiency with and without albuminuria in adults with type 1 diabetes in the diabetes control and complications trial and the epidemiology of diabetes interventions and complications study[J]. Diabetes Care,2010,33(7):1536-1543. [66] He F, Xia X, Wu XF, et al.Diabetic retinopathy in predicting diabetic nephropathy in patients with type 2 diabetes and renal disease: a meta-analysis[J]. Diabetologia,2013,56(3):457-466. [67] Lamb EJ, Levey AS, Stevens PE.The Kidney Disease Improving Global Outcomes (KDIGO) guideline update for chronic kidney disease: evolution not revolution[J]. Clin Chem,2013,59(3):462-465. [68] de Boer IH, Gao X, Cleary PA, et al. Albuminuria Changes and Cardiovascular and Renal Outcomes in Type 1 Diabetes: The DCCT/EDIC Study[J]. Clin J Am Soc Nephrol,2016,11(11):1969-1977. [69] Quiroga B, Arroyo D, de Arriba G. Present and future in the treatment of diabetic kidney disease[J]. J Diabetes Res,2015,2015:801348. [70] Saif A, Soliman N.Urinary α1 -microglobulin and albumin excretion in children and adolescents with type 1 dia-betes[J]. J Diabetes,2017,9(1):61-64. [71] Barrios C, Pascual J, Otero S, et al.Diabetic nephropathy is an independent factor associated to severe subclinical atheromatous disease[J]. Atherosclerosis,2015,242(1):37-44. [72] Khatir DS, Pedersen M, Jespersen B, et al.Evaluation of renal blood flow and oxygenation in CKD using magnetic resonance imaging[J]. Am J Kidney Dis,2015,66(3):402-411. [73] Zhao J, Wang ZJ, Liu M, et al.Assessment of renal fibrosis in chronic kidney disease using diffusion-weighted MRI[J]. Clin Radiol,2014,69(11):1117-1122. [74] Fioretto P, Mauer M.Diabetic nephropathy: diabetic nephropathy-challenges in pathologic classification[J]. Nat Rev Nephrol,2010,6(9):508-510. [75] Tervaert TW, Mooyaart AL, Amann K, et al.Pathologic classification of diabetic nephropathy[J]. J Am Soc Nephrol,2010,21(4):556-563. [76] Armstrong C.ADA Updates Standards of Medical Care for Patients with Diabetes Mellitus[J]. Am Fam Physician,2017,95(1):40-43. [77] Andrassy KM.Comments on 'KDIGO 2012 Clinical Practice Guideline for the Evaluation and Management of Chronic Kidney Disease'[J]. Kidney Int,2013,84(3):622-623. [78] Cherney DZ, Perkins BA, Soleymanlou N, et al.Renal hemodynamic effect of sodium-glucose cotransporter 2 inhibition in patients with type 1 diabetes mellitus[J]. Circulation,2014,129(5):587-597. [79] Levey AS, Coresh J, Balk E, et al.National Kidney Foundation practice guidelines for chronic kidney disease: evaluation, classification, and stratification[J]. Ann Intern Med,2003,139(2):137-147. |
| [1] | Chinese Society of Endocrinology,Chinese Medical Association , et al . Expert suggestion for diabetes management during the recent COVID-19 pandemic [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(02): 136-138. |
| [2] | CHEN Xuyang, GU Weiqiong. Study on detection of insulin autoimmune antibodies: limitation and countermeasures [J]. Journal of Diagnostics Concepts & Practice, 2022, 21(01): 95-98. |
| [3] | WANG Guangyu, YANG Xin, ZHANG Lijuan, TAN Jiaorong. The relationship between plasma total testosterone and osteocalcin levels in males with newly diagnosed type 2 diabetes [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(06): 573-578. |
| [4] | . [J]. Journal of Diagnostics Concepts & Practice, 2021, 20(02): 130-137. |
| [5] | . [J]. Journal of Diagnostics Concepts & Practice, 2020, 19(03): 225-228. |
| [6] | WANG Shanshan, ZHOU Yingxia, HU Lijuan, NIU Jingya, WANG Tiange, LI Mian, ZHAO Zhiyun, XU Yu, LU Jieli, XU Min, BI Yufang, NI Hengru. The correlation between different fat distribution indices and dyslipidemia in middle-aged population in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(2): 177-182. |
| [7] | DENG Lin, DING Yi, WANG Ping, BIAN Bingxian, SHEN Lisong. Application of urinary neutrophil gelatinase-associated lipocalin/creatinine ratio in early diagnosis and severity assessment of renal injury in patients with type 2 diabetes mellitus [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 61-65. |
| [8] | HOU Yanan, XUAN Liping, ZHAO Zhiyun, LI Mian, CHEN Yuhong, DAI Meng, XU Min, BI Yufang, WANG Weiqing, GAO Jinli. Epidemiological study on association of uric acid to creatinine ratio with metabolic syndrome in middle-aged and elderly populationin Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2019, 18(1): 44-50. |
| [9] | XUAN Liping, HOU Yanan, PENG Kui, ZHAO Zhiyun, LI Mian, CHEN Yuhong, DAI Meng, XU Min, BI Yufang, WANG Weiqing, ZHANG Di, XU Jiji. Correlation of subclinical hypothyroidism with carotid intima media thickness in Chinese population [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(04): 444-448. |
| [10] | JI Pengcheng, ZHANG Shu, SUN Jing, JIANG Shihu. Analysis on levels of vitamins in middle-aged and elderly patients with diabetes mellitus in Shanghai [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 285-289. |
| [11] | . [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 357-359. |
| [12] | . [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(03): 352-356. |
| [13] | DU Yiqiao, WANG Wenhui, LIU Wanchao, NIU Jing, SHI Xuejuan, YANG Zhenhua. Establishment of a normal reference range for 1,5-anhydroglucitol [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(02): 181-185. |
| [14] | . [J]. Journal of Diagnostics Concepts & Practice, 2018, 17(01): 5-10. |
| [15] | . [J]. Journal of Diagnostics Concepts & Practice, 2017, 16(05): 553-556. |
| Viewed | ||||||
|
Full text |
|
|||||
|
Abstract |
|
|||||
